What is a stock summary page? Click here for an overview.
Business Description
Niagen Bioscience Inc
NAICS : 541714
SIC : 2833
ISIN : US1710774076
Compare
Compare
Traded in other countries / regions
CDXC.USAOCD1.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2008-06-24Description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.79 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.29 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 11.84 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year Book Growth Rate | 8.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 40.91 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 18.54 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.47 | |||||
| 9-Day RSI | 26.85 | |||||
| 14-Day RSI | 35.69 | |||||
| 3-1 Month Momentum % | 1.63 | |||||
| 6-1 Month Momentum % | 65.68 | |||||
| 12-1 Month Momentum % | 29.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.57 | |||||
| Quick Ratio | 3.06 | |||||
| Cash Ratio | 2.48 | |||||
| Days Inventory | 111.9 | |||||
| Days Sales Outstanding | 25.3 | |||||
| Days Payable | 80.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.3 | |||||
| Shareholder Yield % | 0.17 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.84 | |||||
| Operating Margin % | 7.76 | |||||
| Net Margin % | 8.59 | |||||
| FCF Margin % | 11.99 | |||||
| ROE % | 25.36 | |||||
| ROA % | 14.85 | |||||
| ROIC % | 90.64 | |||||
| 3-Year ROIIC % | -629.02 | |||||
| ROC (Joel Greenblatt) % | 108.26 | |||||
| ROCE % | 19.88 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 60.15 | |||||
| Forward PE Ratio | 51.41 | |||||
| PE Ratio without NRI | 60.15 | |||||
| Price-to-Owner-Earnings | 37.82 | |||||
| PS Ratio | 4.68 | |||||
| PB Ratio | 10.03 | |||||
| Price-to-Tangible-Book | 10.19 | |||||
| Price-to-Free-Cash-Flow | 40.89 | |||||
| Price-to-Operating-Cash-Flow | 39.81 | |||||
| EV-to-EBIT | 61.3 | |||||
| EV-to-EBITDA | 51.43 | |||||
| EV-to-Forward-EBITDA | 77.42 | |||||
| EV-to-Revenue | 4.76 | |||||
| EV-to-Forward-Revenue | 3.58 | |||||
| EV-to-FCF | 39.65 | |||||
| Price-to-GF-Value | 2.62 | |||||
| Price-to-Median-PS-Value | 0.83 | |||||
| Price-to-Graham-Number | 5.23 | |||||
| Price-to-Net-Current-Asset-Value | 11.14 | |||||
| Price-to-Net-Cash | 20.74 | |||||
| Earnings Yield (Greenblatt) % | 1.63 | |||||
| FCF Yield % | 2.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NAGE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Niagen Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 99.597 | ||
| EPS (TTM) ($) | 0.1 | ||
| Beta | 2.28 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 131.31 | ||
| 14-Day RSI | 35.69 | ||
| 14-Day ATR ($) | 0.459893 | ||
| 20-Day SMA ($) | 7.42675 | ||
| 12-1 Month Momentum % | 29.63 | ||
| 52-Week Range ($) | 2.305 - 9.18 | ||
| Shares Outstanding (Mil) | 77.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Niagen Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Niagen Bioscience Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Niagen Bioscience Inc Frequently Asked Questions
What is Niagen Bioscience Inc(NAGE)'s stock price today?
The current price of NAGE is $6.02. The 52 week high of NAGE is $9.18 and 52 week low is $2.31.
When is next earnings date of Niagen Bioscience Inc(NAGE)?
The next earnings date of Niagen Bioscience Inc(NAGE) is 2025-05-08 Est..
Does Niagen Bioscience Inc(NAGE) pay dividends? If so, how much?
Niagen Bioscience Inc(NAGE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers